tbuckley/cabot-search huggingface dataset:
MIR 450b is an Independent Prognostic Marker for Acute Liver Failure in Hepatitis E Infected Pregnant Females
Authors: R. Sehgal, R. Khosla, S. Patra, G.K. Chibbar, S. Kottilil, S.K. Sarin, N. Trehanpati
Journal: Journal of Hepatology (2016)
Role of PET/CT Assesment before Autologous Stem Cell Transplantation in Relapsed or Refractory Lymphoma Patients
Authors: Fátima de la Cruz Vicente, Maria Angeles Domiunguez Muñoz, Estrella Carrillo Cruz, José Francisco Márquez Malaver, Rocio Parody Porras, Jose Francisco Falantes González, Cristina Calderón Cabrera, Olga Pérez López, María Solé Rodríguez, Jose González Campos, María Isabel Montero Cuadrado, María Luz Martino Galiana, Jose Antonio Pérez-Simón, Ildefonso Espigado
Journal: Blood (2014)
Daclatasvir plus Sofosbuvir with or without Ribavirin in Patients with HCV Infection and Decompensated Cirrhosis: Interim Analysis of a French Multicentre Compassionate use Programme
Authors: V. Leroy, C. Hézode, S. Métivier, M. Tateo, F. Conti, E. Nguyen-Khac, D. Lacoste, J. Vergniol, R. Truchi, D. Guyader, G. Riachi, C. Michau, D. Blaison, F. Oberti, H. Fontaine, V. Di Martino, J.-P. Bronowicki, R. Akremi, Y. Bennai, A. Filipovics, G.-P. Pageaux
Journal: Journal of Hepatology (2016)
Deep Proteomic Analysis of Human Erythropoiesis
Authors: Sarah Ducamp, Emilie-Fleur Gautier, Marjorie Leduc, Virginie Salnot, Michael Dussiot, François Guillonneau, Marie-Catherine Giarratana, Luc Douay, Catherine Lacombe, Frederique Verdier, Yael Zermati, Patrick Mayeux
Journal: Blood (2015)
Screening for MPL mutations in Essential Thrombocythemia and Primary Myelofibrosis: Normal Mpl Expression and Absence of Constitutive STAT3 and STAT5 Activation in MPLW515L-Positive Platelets.
Authors: Laura Korin, Ana C Glembotsky, Paola R Lev, Carlos D Chazarreta, Rosana F Marta, Felisa C. Molinas, Paula Graciela Heller
Journal: Blood (2009)
Social selection is a powerful explanation for prosociality
Authors: Randolph M. Nesse
Journal: Behavioral and Brain Sciences (2016)

Abstract Cultural group selection helps explain human cooperation, but social selection offers a complementary, more powerful explanation. Just as sexual selection shapes extreme traits that increase matings, social selection shapes extreme traits that make individuals preferred social partners. Self-interested partner choices create strong and possibly runaway selection for prosocial traits, without requiring group selection, kin selection, or reciprocity.
Routine germline BRCA testing in serous ovarian cancer: The West of Scotland experience.
Authors: Pavlina Spiliopoulou, Sarah Gibson, Rosemarie Davidson, Rosalind Margaret Glasspool, Iain A. McNeish
Journal: Journal of Clinical Oncology (2015)

e16532 Background: Germline mutations in BRCA1/2 (gBRCA) are strongly linked to the development of non-mucinous ovarian cancer (OC), in particular high grade serous OC (HGSOC). Up to 18% unselected patients with HGSOC may harbor mutations. Since Jul 13, all patients with non-mucinous OC in the West of Scotland (WoS) have been offered germline BRCA1/2 testing regardless of family history. All patients received counselling prior to testing. Methods: Sequencing results, derived using chain termination method, were collated with clinical data. Progression-free (PFS) and overall (OS) survivals in gBRCA mutation carriers and non-carriers were compared using Gehan-Breslow-Wilcoxon test. Results: From Jul 13-Nov 14, 154 patients were referred to genetics and 120 accepted testing. gBRCA mutations were identified in 22/120 (18.3%) - 6 BRCA1, 16 BRCA2. An additional 4/120 (3.3%) had variants of unknown significance (VUS). In HGSOC, the mutation rate was 21/92 (22.8%) (6 BRCA1, 15 BRCA2). 50% mutations occurred in women with Manchester score (MS) ≤ 15: these would have been missed if family history alone determined decision to test. gBRCA mutation rate was comparable to that (20%) found in the highly-selected cohort of patients tested in the preceding years (Mar 11-Jun 13). gBRCA1 mutation carriers were significantly younger than gBRCA2 (52 vs 62 years, p = 0.026, gBRCA1: 35-84years, BRCA2: 32-78years). OS for gBRCA2 carriers with stage III/IV HGSOC was significantly better than gBRCA wild-type (HR: 2.25 95%CI 1.05-4.79, p = 0.02, gBRCA wild-type median 63.2m, BRCA2 carriers median undefined). Median PFS of gBRCA2 carriers was also significantly better than gBRCA wild-type (27.9m vs 15.1m, HR 1.8, 95%CI 1.08-3.26 p = 0.02). For gBRCA1carriers both PFS and OS did not differ significantly from non-carriers. Conclusions: Our data confirm that routine germline BRCA1/2 mutation testing is acceptable and feasible in women with OC. Whole population screening is more effective than selection based on family history. c.20% women with HGSOC carry a gBRCA mutation. In WoS, we observe higher prevalence of BRCA2 mutations (16.3%) than previously reported (6-8%). In our cohort, gBRCA2 mutation confers better PFS and OS than wild-type BRCA1/BRCA2 status.
Analysis of Predictive Factors of Non Response to Therapy in Autoimmune Hepatitis-Primary Biliary Cirrhosis Overlap Syndromes a Retrospective Singlecenter Experience
Authors: R. Licinio, A. Facciorusso, N.M. Castellaneta, M. Rendina, S. Carparelli, A. Di Leo
Journal: Journal of Hepatology (2016)
Mid-Infrared Spectroscopy Has a High Sensitivity and Specificity for Point-Of-Care Diagnosis of Non-Alcoholic Steato-Hepatitis
Authors: R. Anty, M. Le Corvec, A. Iannelli, S. Patouraux, M.-C. Saint-Paul, A.-S. Schneck, C. Canivet, I. Ben-Amor, J. Gugenheim, O. Sire, H. Tariel, P. Gual, O. Loréal, A. Tran
Journal: Journal of Hepatology (2016)
Preparation and stability investigation of tamsulosin hydrochloride sustained release pellets containing acrylic resin polymers with two different techniques
Authors: Rui Fan, Yinghua Sun, Bing Li, Ruyi Yang, Wenrui Ma, Jin Sun
Journal: Asian Journal of Pharmaceutical Sciences (2016)

The objective of this study was to prepare tamsulosin hydrochloride-sustained release (TSH-SR) pellets which showed good release stability with frame-controlled method. TSH was added to Eudragit®NE30D and Eudragit®L30D-55 polymers to form drug-loaded inner core. Afterwards, enteric Eudragit®L30D-55 polymer was modified on the surface of it to the final product. Dissolution studies showed that TSH-SR pellets were more stable during the coating process, different curing temperatures and storage conditions compared with TSH pellets produced by film-controlled technique. Appearances and glass transition temperatures (Tgs) of free films and surface morphologies observed by scanning electron microscopy (SEM) of blank sustained release pellets prepared by different ratios of Eudragit®NE30D and Eudragit®L30D-55 further indicated that temperature and relative humidity (RH) were the key factors when Eudragit®NE30D blended with Eudragit®L30D-55 were applied to sustained/controlled release preparations. In addition, SEM identified the surface morphologies of TSH-SR pellets before and after dissolution, which showed intact surface structure and great correlation with release curve respectively.
SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma
Authors: Maite Merino-Azpitarte, Elisa Lozano, María J. Perugorria, Aitor Esparza-Baquer, Oihane Erice, Álvaro Santos-Laso, Colm J. O'Rourke, Jesper B. Andersen, Raúl Jiménez-Agüero, Adelaida Lacasta, Mauro D'Amato, Óscar Briz, Nidhi Jalan-Sakrikar, Robert C. Huebert, Kristen M. Thelen, Sergio A. Gradilone, Ana M. Aransay, José L. Lavín, Maite G. Fernández-Barrena, Ander Matheu, Marco Marzioni, Gregory J. Gores, Luis Bujanda, José J.G. Marin, Jesús M. Banales
Journal: Journal of Hepatology (2017)
Retrospective epidemiologic study to evaluate the pattern of use of biphosphonates in the treatment of bone metastasis in solid tumor cancer patients (REBIUS).
Authors: I. Rodriguez-Penin, M. J. Lamas, A. Iglesias-Santamaria, M. Lema, B. Bernardez, E. Gonzalez-Pereira, F. Busto, B. Matilla, P. Gonzalez, S. Gonzalez-Costas
Journal: Journal of Clinical Oncology (2010)

e19667 Background: Biphosphonates are currently the cornerstone of treatment of bone metastasis. This is a retrospective observational multicentric study to describe the pattern of use of biphosphonates in the clinical practice in 10 hospitals in the northwestern region of Spain. Methods: patients older than 18 years receiving biphosphonates for bone metastasis from a solid tumor between 15 and 30 September 2007 were included. Data were obtained from electronic records and clinical histories from the beginning of treatment to the end or 30 march 2008. Results: 130 patients were assessed, 66% women and 34% men. Median age was 68 (38.7-93.4). Initial ECOG PS was 0-1 for 89%, 2 for 11%. None had renal failure before biphosphonates, and 14.6% (26.4% pathological fractures) had previous skeletal related events (SREs). Primary tumor was breast in 57.7%, prostate in 21.5%, lung in 6.9% and others in 13.9% patients. Initial mean plasmatic creatinine (Cr) was 0.87 mg/dl (SD ±0.16). Zoledronic acid (Zol) was used in 93.1% patients (60.2% every 4 weeks, 36.4% every 3, 3.4% e/6ws) and pamidronic acic (Pam) in 6.9%. 52.2% received oral calcium concomitantly. Previous antineoplasic agents were administered to 65 patients and 83.4% patients received concomitant antineoplasic treatment, at least 52.3% more than one line. Adverse reactions related to biphosphonates appeared in 51 people: 15.7% hyperthermia, 9.8% osteonecrosis of the jaw (ONJ), 5.9% renal damage (Cr>3 mg/dl) and 5.9% hypocalcaemia mainly. 1 case of cephalea, 2 of ONJ, 1 of hyperthermia and 1 renal event had a severity of grade 3 (NCI CTC v3.0). Treatment was discontinued in 14.6% patients: none for a new SRE, 1 for toxicity, and 15 for death or severe deterioration due to cancer. Median duration of treatment was 11.2 months (0.7-56.1) for Zol and 35.1 months (10.3-49.6) for Pam. At the end of the follow up 59.2% went on biphosphonates. Conclusions: Biphosphonates iv are the option chosen to treat bone metastasis. Long term safety in clinical practice is the expected based on other experiences. Biphosphonates are not discontinued after disease progression and tends to be used until the end of life. No significant financial relationships to disclose.
Testosterone supplementation for “low T” is not supported by evidence, review concludes
Authors: Michael McCarthy
Journal: BMJ (2016)

Evidence from randomized controlled trials does not support the use of testosterone supplementation for the treatment of symptoms often ascribed to low testosterone concentrations or “low T,” a systematic review has found.1

Adriane Fugh-Berman, of Georgetown University Medical Center in Washington, DC, who led the new study, said that the findings indicated that testosterone products were being marketed for many symptoms that were, in fact, part of normal ageing. “Testosterone has known risks and no clear benefits and shouldn’t be used by men with intact testicles,” Fugh-Berman said. …
P2.18: Rapid On-Site Evaluation (ROSE) Technique: Experience in the Pulmonology Unit of a Reference Hospital in Latin America
Authors: Liliana Fernandez, Luz F. Sua, Juliana Escobar, Liliana Leon, Mauricio Velasquez, Fernando Sanabria, William Martinez, Leidys Gutiérrez
Journal: Journal of Thoracic Oncology (2016)
Prognostic Utility of a New mRNA Expression Signature of Gleason Score
Authors: Jennifer A. Sinnott, Sam F. Peisch, Svitlana Tyekucheva, Travis Gerke, Rosina Lis, Jennifer R. Rider, Michelangelo Fiorentino, Meir J. Stampfer, Lorelei A. Mucci, Massimo Loda, Kathryn L. Penney
Journal: Clinical Cancer Research (2016)

Abstract Purpose: Gleason score strongly predicts prostate cancer mortality; however, scoring varies among pathologists, and many men are diagnosed with intermediate-risk Gleason score 7. We previously developed a 157-gene signature for Gleason score using a limited gene panel. Using a new whole-transcriptome expression dataset, we verified the previous signature's performance and developed a new Gleason signature to improve lethal outcome prediction among men with Gleason score 7. Experimental Design: We generated mRNA expression data from prostate tumor tissue from men in the Physicians' Health Study and Health Professionals Follow-Up Study (N = 404) using the Affymetrix Human Gene 1.0 ST microarray. The Prediction Analysis for Microarrays method was used to develop a signature to distinguish high (≥8) versus low (≤6) Gleason score. We evaluated the signature's ability to improve prediction of lethality among men with Gleason score 7, adjusting for 3 + 4/4 + 3 status, by quantifying the area under the receiver operating characteristic (ROC) curve (AUC). Results: We identified a 30-gene signature that best distinguished Gleason score ≤6 from ≥8. The AUC to predict lethal disease among Gleason score 7 men was 0.76 [95% confidence interval (CI), 0.67–0.84] compared with 0.68 (95% CI, 0.59–0.76) using 3 + 4/4 + 3 status alone (P = 0.0001). This signature was a nonsignificant (P = 0.09) improvement over our previous signature (AUC = 0.72). Conclusions: Our new 30-gene signature improved prediction of lethality among men with Gleason score 7. This signature can potentially become a useful prognostic tool for physicians to improve treatment decision making. Clin Cancer Res; 23(1); 81–87. ©2016 AACR. See related commentary by Yin et al., p. 6
Decreased MIR-425 Induced Inflammatory Cytokine Production via N-RAS Upregulation in CD4+ T Cells of Primary Biliar Cholangitis
Authors: R. Nakagawa, R. Muroyama, K. Koike, C. Saeki, S. Ito, S. Morimoto, K. Goto, Y. Matsubara, N. Kato, M. Zeniya
Journal: Journal of Hepatology (2016)
Identification of epigenetic silencing of GCNT2 expression by comprehensive real-time PCR screening in colorectal cancer.
Authors: Kazunorii Nakamura, Horomichi Sawaki, Keishi Yamashita, Masahiko Watanabe, Hisashi Narimatsu
Journal: Journal of Clinical Oncology (2014)

506 Background: Glycoprotein expression profile has been proved to be dramatically altered in human cancers, however specific glycogenes which are aberrant in expression in cancer cells has not been fully identified. Recent accumulated evidence supported notion that the reduced expression of tumor suppressor genes is explained by DNA promoter methylation in human cancer. Methods: We used Comprehensive Real time PCR system (CRPS) for glycogenes (189 genes) to identify genes aberrantly expressed in colorectal cancer tissues (CRC) as compared to the corresponding normal mucosa tissues. GCNT2 was of particular interest among the identified genes in CRC. Results: (1) GCNT2 harbors 3 isoforms which have different promoter regions. (2) All of the 3 isoforms of GCNT2 genes were remarkably decreased in CRC as compared to the corresponding normal mucosa, and each isoform expression was strongly associated with other 2 isoforms in primary cancer tissues by TaqMan real time PCR (R = 0.99-995, p &lt; 0.0001). (3) Among the 5 CRC cell lines (DLD1, HCT116, CACO2, LOVO), those which were silenced in expression were reactivated by demethylating agents such as 5-aza-2’ deoxycytidine and trichostatin A. (4) Promoter region of the variant 2 of GCNT2 was consistent with its silenced expression in CRC cell lines by cloned sequence, so we examined DNA methylation status of the promoter of the GCNT2 variant 2 in 50 primary cancer tissues and the corresponding normal tissues. Quantitative MSP revealed that almost half of normal tissues have methylation as high as tumor tissues, while, in the primary CRC with less methylation in the corresponding normal tissues, DNA methylation was higher in primary CRC tissues than in the corresponding normal tissues. Finally, GCNT2 variant 2 stable transfection induced expression of other 2 isoform variants. Conclusions: We identified novel methylation gene GCNT2 among the glycoenes. Glycoenes that were altered in genomic or epigenetic manner have been few, so GCNT2 may play a critical role in cancer progression through glycan change.
HBsAg Loss is Enough to Discontinue Long-Term Nucleos (T)IDE Analogue Therapy in HBeAg-Negative Chronic Hepatitis B Patients in Real Practice?
Authors: M. Fasano, M. Ciarallo, G. Niro, R. Fontana, R. Cozzolongo, A. Maci, I. Carraturo, A. Miglietta, G. Angarano, T. Santantonio
Journal: Journal of Hepatology (2016)
Humanized Anti-CD26 Monoclonal Antibody Inhibits Osteoclast Bone Resorption Activity Via Blockade Of P38MAPK Signaling In Multiple Myeloma
Authors: Hiroko Nishida, Hiroko Madokoro, Hiroshi Suzuki, Michiie Sakamoto, Chikao Morimoto, Taketo Yamada
Journal: Blood (2013)
P23 Q/A METHOD -A novel way of assessing pulmonary artery stiffness in COPD using cardiac MRI: Abstract P23 Table 1
Authors: S Saikia, NS Gale, JCL Rodrigues, RG Wise, C Bucciarelli-Ducci, JR Cockcroft, DJ Shale
Journal: Thorax (2015)

<h3>Background</h3> Pulmonary artery distensibility and pulsatility has been studied in patients with COPD using cardiac MRI (CMRI).<sup>1</sup> However, pulmonary artery pulse wave velocity (PA-PWV) using the ‘QA’method<sup>2</sup> in CMRI has not been studied in this population. We hypothesised that patients with COPD have a higher PA-PWV compared to healthy individuals. <h3>Methods</h3> This interim analysis includes 23 COPD and 12 healthy volunteers (current or ex-smokers free from respiratory disease). All participants underwent spirometry to measure FeV1, FVC and their ratio, oxygen saturations, heart rate, peripheral mean arterial pressure (MAP), 6-minute-walk-distance (6MWD) and cardiac MRI to measure PA-PWV. MRI studies were performed using a 3.0T GE Signa HDx MRI scanner (GE Healthcare). Phase-contrast cross-sectional images of the pulmonary artery using steady-state free precession sequence were obtained, approximately 2 cm above the pulmonary valve, under free-breathing conditions. <h3>Results</h3> Patients with COPD and the healthy individuals were similar in age and gender (Table 1). Patients with COPD had impaired lung function, greater PA-PWV (3.37 ± 0.62 vs 1.4 ± 0.4, p = &lt;0.001*), heart rate and mean arterial pressure than the healthy individuals. Male patients with COPD had greater PA-PWV (3.63 ± 0.45) than females (3.11 ± 0.59) p = 0.042. PA-PWV did not relate to age, lung function, resting oxyyen saturations, heart rate or peripheral MAP. <h3>Conclusion</h3> Pulmonary artery PWV measured using CMRI ‘QA’ method showed that COPD patients have a stiffer pulmonary artery than healthy individuals. Further analysis will investigate the association between pulmonary artery stiffness and cardiac function. <h3>References</h3> 1 Liu C-Y, Jiang R, Dashnaw S, <i>et al</i>. Pulmonary artery stiffness in chronic obstructive pulmonary disease (COPD) - the MESA COPD study. <i>JCMR</i> 2011;<b>13</b>(Suppl 1):P73 2 Peng H-H, Chung HW, Yu HY, Tseng WY. Estimation of pulse wave velocity in main pulmonary artery with phase contrast MRI: preliminary investigation.<i> JMRI</i> 2006;<b>24</b>:1303–1310
Moth-Associated Dermatitis—Cozumel, Mexico
Journal: JAMA (1990)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Results of Radiofrequency Ablation in a Cohort of Cirrhotic Patients at Liver Transplantation
Authors: M.H. Conde, F. Pons, E. Llop, C. Perelló, J. De la Revilla, N. Fernández Puga, J.L. Martínez Porras, M. Trapero, S. Méndez, V. Cuervas-Mons, V. Sánchez-Turrión, J.L. Calleja Panero
Journal: Journal of Hepatology (2016)
Prognostic value of <i>CDH2</i> and <i>CDT2</i> expression levels in the peripheral blood (PB) specimens of patients with Ewing family of tumors (EFTs).
Authors: Joanna Przybyl, Maria Debiec-Rychter, Tomasz Switaj, Hanna Melania Kosela, Slawomir Falkowski, Katarzyna Wiater, Iwona Lugowska, Anna Szumera-Cieckiewicz, Konrad Ptaszynski, Janusz A. Siedlecki, Piotr Rutkowski
Journal: Journal of Clinical Oncology (2013)

e22046 Background: EFTs are characterized by oncogenic EWSR1-FLI1 fusion gene, which can be detected in 85-90% of tumors and in 20-70% of peripheral blood specimens. It has been previously reported that downregulation of CDH2 (encoding N-cadherin) and overexpression of CDT2 [also known as DTL, encoding denticleless homolog (Drosophila)]in EFTs tumors are associated with poor prognosis. The aim of the study was to evaluate the expression levels of these markers in the circulating tumor cells and assess their utility as prognostic markers in EFTs. Methods: 10mL of PB was collected from 24 untreated adult EFTs patients at the diagnosis (period: 2009-2011, median age 30 years). 9 blood specimens from healthy individuals, and 5 untreated frozen EFTs tumor samples were used as controls. 8 EFTs patients presented metastatic disease (M1) at the diagnosis and 5 patients died during the follow-up period. Median follow-up was 22 months. Quantitative reverse transcription PCR (qRT-PCR) for CDH2 and CDT2 expression were performed in triplicate using the TaqMan Gene Expression Assays (Applied Biosystems). Mean expression level of 2 reference genes PSMC4 and EIF2B1 served as endogenous control. The fold change was calculated using ddCt method with pooled healthy individuals as calibrator. Results: At least 2-fold decrease (range 2.11-16.35) of CDH2 expression level in PB has been observed in 79% (n=19) of EFTs patients (p=0.04) as compared to healthy control. In general, CDH2 expression level in PB of EFTs patients was 3.08-fold lower compared with healthy individuals (p=0.07). All of the patients who had M1 at diagnosis (n=8) and who died during the follow-up (n=5) had CDH2 gene underexpression. CDT2 overexpression (FC range 3.28-6.97) has been observed in 17% (n=4) of EFTs patients (p=0.01). Three of these patients had M1 at diagnosis and two of these patients died during the follow-up. PB specimens presenting CDT2 overexpression clustered together with the tumor specimens. Conclusions: Abnormalities in the expression of CDH2 and CDT2 genes in PB specimens are associated with aggressive clinical course of EFTs. Diagnostic and prognostic significance of these biomarkers warrants further studies.